GlassScriptPhysician profile
James S Morris
NPI 1043271497
$7,539.57
in general payments reported to CMS, 2019-2025
43 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $913 · 2021: $1,314 · 2022: $1,083 · 2023: $1,150 · 2024: $1,104 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,375 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,374.99 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $879.75 | 2019-2025 | |
| Antares Pharma, INC. | $832.09 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $804.08 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $551.45 | 2019-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $506.17 | 2019-2025 | |
| Allergan, INC. | $476.44 | 2019-2022 | |
| Boston Scientific Corporation | $449.17 | 2019-2025 | Exalt Model D, Ams 700, Ams 800 Artificial Urinary Sphincter |
| Urogen Pharma, INC. | $350.54 | 2021-2025 | Jelmyto |
| Pfizer INC. | $331.53 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $307.50 | 2019-2025 | Provenge |
| Blue Earth Diagnostics | $251.38 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $163.95 | 2019-2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $161.31 | 2023-2025 | Gemtesa, Orgovyx |
| Astrazeneca Pharmaceuticals LP | $151.55 | 2020-2025 | Lynparza, Imfinzi |
| Caldera Medical, INC | $139.26 | 2024 | Desara |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $122.70 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $109.77 | 2020-2024 | Keytruda, Lynparza |
| Myriad Genetic Laboratories, INC. | $100.38 | 2023-2024 | Prolaris |
| Accord Healthcare, INC. | $100.30 | 2022-2024 | |
| Endo Pharmaceuticals INC. | $93.78 | 2019-2023 | Aveed, Xiaflex |
| Acerus Pharmaceuticals Corporation | $59.09 | 2020-2021 | |
| Urovant Sciences INC | $58.19 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $49.70 | 2021-2023 | Pylarify |
| Axonics, INC. | $46.04 | 2020-2023 | Bulkamid |
| Myovant Sciences INC. | $45.71 | 2021-2022 | |
| Halozyme INC | $43.13 | 2023 | |
| Clarus Therapeutics INC. | $34.08 | 2021 | |
| Tolmar, INC. | $33.22 | 2024-2025 | Eligard, Jatenzo |
| Coloplast Corp | $30.76 | 2020-2022 | |
| Rochester Medical Corporation | $28.15 | 2019-2020 | |
| Procept Biorobotics Corporation | $25.72 | 2021 | |
| Travere Therapeutics, INC. | $25.33 | 2019-2020 | |
| Intuitive Surgical, INC. | $24.01 | 2019 | |
| Foundation Medicine, INC. | $23.45 | 2022 | |
| Endo USA, INC. | $20.07 | 2024 | Xiaflex, Aveed |
| Agiliti Surgical, INC. | $18.79 | 2019 | |
| Olympus America INC. | $16.13 | 2025 | Itind System |
| Kerecis Limited | $15.45 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Ethicon US, LLC | $14.10 | 2020 | |
| Verity Pharmaceuticals INC. | $13.89 | 2024 | Trelstar |
| Zyla Life Sciences, INC. | $12.44 | 2020 | |
| Photocure INC | $11.66 | 2022 | |
| Ambu INC. | $7.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.